IGF1 and non-small cell lung carcinoma: In non-small cell lung cancer, IGF-1 treatment of erlotinib-inhibited cells increased IGF1R/EGFR heterodimerization, leading to mTOR-mediated synthesis of EGFR and survivin, which counteracted the antiproliferative effects of Erlotinib (24).